Grail Q2 revenue rises 26%, net loss narrows 3%

Grail

05/08/2026 21:11

Overview
US cancer screening test maker's Q2 revenue rose 26% yr/yr, Galleri test revenue up 24%
Net loss for Q2 narrowed 3% from prior year
Company completed $110 mln equity financing with Samsung to expand in Asia

Outlook
Company anticipates FDA advisory committee review of Galleri test PMA application in the fall
Company plans to expand Galleri test commercialization in South Korea and potentially other Asian markets
Company continues to expand field sales and medical teams to drive Galleri test commercial momentum

Result Drivers
TEST VOLUME GROWTH - Galleri test volume increased 35% yr/yr to over 61,000, driving higher revenue
CLINICAL TRIAL DATA - Company cited positive results from NHS-Galleri and PATHFINDER 2 studies as supporting adoption of Galleri test
COMMERCIAL PARTNERSHIPS - Expanded access through new and existing partnerships, including collaboration with Priority Health and Samsung

Company press release: ID:nPnc3npn3a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$110.25 mln
 
Q2 Income from Operations
 
-$173.78 mln
 
Q2 Loss Per Basic Share
 
$2.56
 
Q2 Pretax Loss
 
$166.71 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Grail Inc is $63.07, about 13.3% below its August 4 closing price of $72.70

Reuters Recommended Reads
Aug 4 - Switzerland's SOPHiA GENETICS Q2 revenue rises on Liquid Biopsy growth
Aug 4 - Personalis Q2 revenue rises 30%, beats estimates on expanded Medicare coverage
Aug 3 - GeneDx Q2 revenue beats analyst estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)